Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[64Cu]FBP8
- Development stage
- Phase 3
- Lead developer
- Massachusetts General Hospital
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Positron Emitters → Radiopharmaceuticals, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Administration
- Intravenous Injection
01
Overview
[64Cu]FBP8 is a radiopharmaceutical diagnostic agent consisting of a cyclic peptide (fibrin binding probe 8) labeled with the radioisotope copper-64. It is designed for positron emission tomography (PET) imaging to detect and localize fibrin-rich blood clots (thrombi) throughout the body. The mechanism of action involves specific binding to fibrin within thrombi, enabling visualization and quantification of clot burden in conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), and venous thromboembolism. The agent demonstrates rapid renal clearance and low background signal in non-target tissues. Developed primarily by The General Hospital Corp./Massachusetts General Hospital, it is being investigated for its ability to non-invasively image thrombosis and assess brain fibrin content in neurodegenerative diseases such as Alzheimer's disease[2][4][6].
- Other names
- fibrin binding probe 8FBP8FBP-8FBP 8
02
Targets
Fibrin (Factor Ia)
Beyond the preview
Go deeper on [64Cu]FBP8.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [64Cu]FBP8.